CVS Health has confirmed it will break itself into two separate companies, unwinding the healthcare conglomerate it spent years assembling. The move, announced after the market close, sent shares down 12.6% as investors reacted to the scale and timeline of the overhaul.
The company said the split should be completed in the first half of 2028. Under the plan, existing shareholders will receive shares in both new entities. One company will house the Aetna insurance arm, the Caremark pharmacy-benefit manager (PBM), and related businesses like specialty pharmacy, Oak Street Health, and Signify Health. The other will be a standalone retail pharmacy chain with roughly 9,000 stores, MinuteClinics, and mail-order services.
Why CVS is breaking up its one-stop shop
For years, CVS pursued a strategy of vertical integration—bringing an insurer, a drug-price negotiator, and a pharmacy chain under one roof. It bought Caremark in 2006 and acquired Aetna for $78 billion in 2018, betting that combining these pieces would create a seamless healthcare experience and capture more of every healthcare dollar.
But the environment has shifted. Regulators and large corporate clients have grown more wary of vertical integration, worried about conflicts of interest when one company both decides which drugs are covered and fills the prescriptions. At the same time, health insurers have been squeezed by higher medical costs, while drugstores face weaker foot traffic and intense online competition.
Management insists the underlying operations are performing well. The breakup, they argue, is about responding to a changed landscape rather than fixing a broken business.
What the split means for investors
Breakups are often as much about valuation as strategy. Investors tend to apply a "conglomerate discount" to complex companies, valuing them lower than the sum of their parts. That discount can be especially steep when regulatory or political scrutiny hangs over the business model.
Morningstar analyst Julie Utterback noted that CVS has "the most exposure to vertical integration" scrutiny, and that kind of overhang can keep valuation multiples depressed even if profits hold up. By separating the retail pharmacies from Aetna and Caremark, each business becomes easier to compare with pure-play peers, and the conflict-of-interest narrative loses some force.
The key question from now until 2028 is not just whether earnings meet expectations, but whether the market starts assigning two clearer, peer-like valuations instead of one blended, discounted "CVS conglomerate" multiple.
What to watch next
Investors will be watching for details on the capital structure of each new company, any regulatory hurdles, and how the separation will be executed without disrupting operations. The timeline is long, and there's plenty of room for the plan to change.
For everyday investors, the takeaway is that CVS is making a strategic bet that its parts are worth more apart than together. That's a common theme in corporate America, and it doesn't always work out. But for a company that has been under pressure from multiple directions, the split offers a clearer path for each business to focus on its own challenges.
As the healthcare sector continues to evolve, other healthcare stocks have also seen sharp moves, and CVS's exploration of a split had been rumored for months. Now that it's official, the focus shifts to execution.
Breakups like this are rarely quick or easy. But for CVS, the hope is that by 2028, investors will see two focused companies rather than one complicated one—and value them accordingly.
